These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27565902)

  • 21. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Schenk JM; Song Y; Arnold KB; Neuhouser ML; Goodman PJ; Lin DW; Stanczyk FZ; Thompson IM
    Am J Epidemiol; 2008 Dec; 168(12):1416-24. PubMed ID: 18945688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
    Kaplan SA; Lee JY; Meehan AG; Kusek JW
    J Urol; 2016 Jun; 195(6):1825-9. PubMed ID: 26678956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.
    Morales EE; Grill S; Svatek RS; Kaushik D; Thompson IM; Ankerst DP; Liss MA
    Eur Urol; 2016 Mar; 69(3):407-10. PubMed ID: 26320383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.
    Schenk JM; Kristal AR; Arnold KB; Tangen CM; Neuhouser ML; Lin DW; White E; Thompson IM
    Am J Epidemiol; 2011 Jun; 173(12):1419-28. PubMed ID: 21540324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality-of-life findings for the prostate cancer prevention trial.
    Moinpour CM; Darke AK; Donaldson GW; Cespedes D; Johnson CR; Ganz PA; Patrick DL; Ware JE; Shumaker SA; Meyskens FL; Thompson IM
    J Natl Cancer Inst; 2012 Sep; 104(18):1373-85. PubMed ID: 22972968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
    Murtola TJ; Tammela TL; Määttänen L; Ala-Opas M; Stenman UH; Auvinen A
    Br J Cancer; 2009 Sep; 101(5):843-8. PubMed ID: 19654575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
    Schmidt LJ; Tindall DJ
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
    de la Taille A
    Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prevention of prostate cancer. Long-term results of the Prostate Cancer Prevention Trial (PCPT)].
    Michel MS; Nitschmann S; von Hardenberg J
    Internist (Berl); 2014 Aug; 55(8):981-2. PubMed ID: 25027005
    [No Abstract]   [Full Text] [Related]  

  • 39. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.